替格瑞洛片联合阿司匹林肠溶片用于经皮冠状动脉介入治疗术后急性心肌梗死患者的临床研究  

Clinical trial of tegrilol tablets and aspirin enteric coated tablets in the treatment of patients with acute myocardial infarction after percutaneous coronary intervention

作　　者：李拜红 施晶晶 鲍骏 蔡文渊 金伟东 王晓彦 LI Bai-hong;SHI Jing-jing;BAO Jun;CAI Wen-yuan;JIN Wei-dong;WANG Xiao-yan(Department of Cardiology,Affiliated Hospital of Jiangnan University/Wuxi Integrated Hospital of Traditional Chinese and Western Medicine,Wuxi 214041,Jiangsu Province,China)

机构地区：[1]江南大学附属医院、无锡市中西医结合医院心内科,江苏无锡214041

出　　处：《中国临床药理学杂志》2021年第19期2558-2561,共4页The Chinese Journal of Clinical Pharmacology

基　　金：江苏省自然科学基金资助项目(BK2011382);无锡市卫生和计划生育科研课题资助项目(MS201514)。

摘　　要：目的观察替格瑞洛片联合阿司匹林肠溶片用于经皮冠状动脉介入治疗(PCI)术后急性心肌梗死(AMI)患者的临床疗效及安全性。方法将168例PCI术后AMI患者随机分为对照组83例和试验组85例。对照组给予阿司匹林肠溶片300 mg+硫酸氢氯吡格雷片600 mg,PCI术前顿服,术后给予阿司匹林肠溶片每次100 mg,qd,口服+硫酸氢氯吡格雷片每次75 mg,qd,口服;试验组给予阿司匹林肠溶片300 mg+替格瑞洛片180 mg,PCI术前顿服,术后给予阿司匹林肠溶片每次100 mg,qd,口服+替格瑞洛片每次90 mg,qd,口服。2组患者均治疗6个月。比较2组患者的冠状动脉血流参数,心血管不良事件(MACE)发生率,以及药物不良反应的发生情况。结果试验过程中脱落14例。PCI术后24 h,试验组和对照组的左前降支舒张期血流峰值分别为(34.69±4.15)和(29.04±3.26) cm·s-1,收缩期血流峰值分别为(16.26±2.18)和(13.85±1.73) cm·s-1,冠状动脉血流储备分别为3.35±0.42和2.79±0.36,差异均有统计学意义(均P <0.05)。治疗期间,试验组和对照组的MACE发生率分别为10.00%(8例/80例)和25.68%(19例/74例),差异有统计学意义(P <0.05)。试验组的药物不良反应主要有牙龈出血、鼻出血和皮肤出血,对照组的药物不良反应主要有牙龈出血、鼻出血和皮肤出血。试验组和对照组的总药物不良反应发生率分别为22.50%和16.22%,差异无统计学意义(P> 0.05)。结论替格瑞洛片联合阿司匹林肠溶片治疗PCI术后AMI患者的临床疗效确切,MACE发生率较低,且不增加药物不良反应的发生率。Objective To observe the clinical efficacy and safety of tegrilol tablets and aspirin enteric coated tablets in the treatment of patients with acute myocardial infarction(AMI) after percutaneous coronary intervention(PCI).Methods A total of 168 patients with AMI after PCI were randomly divided into control group 83 cases and treatment groups 85 cases.The control group was given aspirin enteric coated tablets 300 mg,qd,orally+clopidogrel bisulfate tablets 600 mg,orally before PCI,and then was given aspirin enteric coated tablets 100 mg per time+clopidogrel bi sulfate tablets 75 mg per time,qd,orally after PCI.The treatment group was given aspirin enteric coated tablets 300 mg+tegrilol tablets 180 mg,orally before PCI,and then was given aspirin enteric coated tablets 100 mg per time,qd,orally+tegrilol tablets 90 mg per time,qd,orally.The two groups were both treated for 6 months.The coronary flow parameters,the incidence of adverse cardiovascular events(MACE) and adverse drug reactions were compared between the two groups.Results There were 14 cases of shedding during the trial.24 h after PCI,the diastolic peak of left anterior descending branch in the treatment and control groups were(34.69±4.15) and(29.04±3.26)cm·s-1,systolic peak blood flow were(16.26±2.18) and(13.85±1.73) cm·s-1,coronary flow reserve were3.35±0.42 and 2.79±0.36,the differences were all statistically significant(all P <0.05).During the treatment,the incidences of MACE in the treatment and control groups were 10.00%(8 cases/80 cases) and 25.68%(19 cases/74 cases) with significant difference(P <0.05).The adverse drug reactions of treatment group were gum bleeding,nose bleeding and skin bleeding,while those in control group were gum bleeding,nose bleeding and skin bleeding.The total incidences of adverse drug reactions in the treatment and control groups were 22.50% and 16.22%without significant difference(P>0.05).Conclusion Tegrilol tablets combined with aspirin enteric coated tablets have a definitive clinical efficacy in the treatment of

关 键 词：替格瑞洛片 阿司匹林肠溶片 硫酸氢氯吡格雷片 急性心肌梗死 经皮冠状动脉介入治疗 安全性评价 

分 类 号：R972[医药卫生—药品]